UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
Autologous stem cell transplantation is considered the standard of care for multiple myeloma patients aged < 65 years with no relevant comorbidities. The addition of drugs acting both on bone marrow microenvironment and on neoplastic plasma cells has significantly increased the proportion of pati...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2012-11-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/358 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850283272206024704 |
|---|---|
| author | Patrizia Tosi Manuela Imola Mianulli Anna Maria Simona Tomassetti Anna Merli Annalia Molinari Serena Mangianti Marina Ratta Alessandro Isidori Giuseppe Visani |
| author_facet | Patrizia Tosi Manuela Imola Mianulli Anna Maria Simona Tomassetti Anna Merli Annalia Molinari Serena Mangianti Marina Ratta Alessandro Isidori Giuseppe Visani |
| author_sort | Patrizia Tosi |
| collection | DOAJ |
| description | Autologous stem cell transplantation is considered the standard of care for multiple myeloma patients aged < 65 years with no relevant comorbidities. The addition of drugs acting both on bone marrow microenvironment and on neoplastic plasma cells has significantly increased the proportion of patients achieving a complete remission after induction therapy, and these results are mantained after high-dose melphalan, leading to a prolonged disease control. Studies are being carried out in order to evaluate whether short term consolidation or long-term maintenance therapy can result into disease eradication at the molecular level thus increasing also patients survival. The efficacy of these new drugs has raised the issue of deferring the transplant after achivng a second response upon relapse. Another controversial point is the optimal treatment strategy for high-risk patients, that do not benefit from autologous stem cell transplantation and for whom the efficacy of new drugs is still matter of debate. |
| format | Article |
| id | doaj-art-10e5a62c12104e1cbe912711cb09e31e |
| institution | OA Journals |
| issn | 2035-3006 |
| language | English |
| publishDate | 2012-11-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-10e5a62c12104e1cbe912711cb09e31e2025-08-20T01:47:48ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062012-11-0141e2012069e201206910.4084/mjhid.2012.069250UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMAPatrizia Tosi0Manuela Imola1Mianulli Anna Maria2Simona Tomassetti3Anna Merli4Annalia Molinari5Serena Mangianti6Marina Ratta7Alessandro Isidori8Giuseppe Visani9UO Ematologia, Ospedale Infermi Rimini ItalyUO Ematologia, Ospedale Infermi Rimini ItalyUO Ematologia, Ospedale Infermi Rimini ItalyUO Ematologia, Ospedale Infermi Rimini ItalyUO Ematologia, Ospedale Infermi Rimini ItalyUO Ematologia, Ospedale Infermi Rimini ItalyUO Ematologia, Ospedale Infermi Rimini ItalyUO Ematologia, Ospedale Infermi Rimini ItalyEmatologia e Centro Trapianti AORMN Marche Nord Pesaro ItalyEmatologia e Centro Trapianti AORMN Marche Nord Pesaro ItalyAutologous stem cell transplantation is considered the standard of care for multiple myeloma patients aged < 65 years with no relevant comorbidities. The addition of drugs acting both on bone marrow microenvironment and on neoplastic plasma cells has significantly increased the proportion of patients achieving a complete remission after induction therapy, and these results are mantained after high-dose melphalan, leading to a prolonged disease control. Studies are being carried out in order to evaluate whether short term consolidation or long-term maintenance therapy can result into disease eradication at the molecular level thus increasing also patients survival. The efficacy of these new drugs has raised the issue of deferring the transplant after achivng a second response upon relapse. Another controversial point is the optimal treatment strategy for high-risk patients, that do not benefit from autologous stem cell transplantation and for whom the efficacy of new drugs is still matter of debate.http://www.mjhid.org/index.php/mjhid/article/view/358Autologous transplantation myeloma |
| spellingShingle | Patrizia Tosi Manuela Imola Mianulli Anna Maria Simona Tomassetti Anna Merli Annalia Molinari Serena Mangianti Marina Ratta Alessandro Isidori Giuseppe Visani UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Mediterranean Journal of Hematology and Infectious Diseases Autologous transplantation myeloma |
| title | UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA |
| title_full | UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA |
| title_fullStr | UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA |
| title_full_unstemmed | UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA |
| title_short | UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA |
| title_sort | update on the role of autologous hematopoietic stem cell transplantation in multiple myeloma |
| topic | Autologous transplantation myeloma |
| url | http://www.mjhid.org/index.php/mjhid/article/view/358 |
| work_keys_str_mv | AT patriziatosi updateontheroleofautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT manuelaimola updateontheroleofautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT mianulliannamaria updateontheroleofautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT simonatomassetti updateontheroleofautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT annamerli updateontheroleofautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT annaliamolinari updateontheroleofautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT serenamangianti updateontheroleofautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT marinaratta updateontheroleofautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT alessandroisidori updateontheroleofautologoushematopoieticstemcelltransplantationinmultiplemyeloma AT giuseppevisani updateontheroleofautologoushematopoieticstemcelltransplantationinmultiplemyeloma |